Does the media prefer ABUS or ARQT?

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 3 mentions for Arbutus Biopharma. Arcutis Biotherapeutics' average media sentiment score of 1.35 beat Arbutus Biopharma's score of 1.19 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABUS or ELVN?

In the previous week, Enliven Therapeutics had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Enliven Therapeutics and 3 mentions for Arbutus Biopharma. Enliven Therapeutics' average media sentiment score of 1.19 beat Arbutus Biopharma's score of 1.19 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GMTX or ABUS?

Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 13.12%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Arbutus Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ABUS or IDYA?

In the previous week, IDEAYA Biosciences had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for IDEAYA Biosciences and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat IDEAYA Biosciences' score of 0.75 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MBX or ABUS?

In the previous week, MBX Biosciences had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for MBX Biosciences and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat MBX Biosciences' score of 0.85 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arbutus Biopharma (ABUS) Competitors

$4.42 +0.06 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$4.42 +0.00 (+0.11%)

As of 05:34 PM Eastern

Compare

ABUS vs. ARQT, ELVN, GMTX, IDYA, and MBX

Should you buy Arbutus Biopharma stock or one of its competitors? MarketBeat compares Arbutus Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arbutus Biopharma include Arcutis Biotherapeutics (ARQT), Enliven Therapeutics (ELVN), Gemini Therapeutics (GMTX), IDEAYA Biosciences (IDYA), and MBX Biosciences (MBX).

How does Arbutus Biopharma compare to Arcutis Biotherapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 3 mentions for Arbutus Biopharma. Arcutis Biotherapeutics' average media sentiment score of 1.35 beat Arbutus Biopharma's score of 1.19 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 13.12%. Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 30.62%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arbutus Biopharma's return on equity of 129.32% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

43.8% of Arbutus Biopharma shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has higher revenue and earnings than Arbutus Biopharma. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.01	-$33.50M	$0.83	5.33
Arcutis Biotherapeutics	$376.07M	8.66	-$16.14M	-$0.03	N/A

Summary

Arbutus Biopharma and Arcutis Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Enliven Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.01	-$33.50M	$0.83	5.33
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Arbutus Biopharma currently has a consensus target price of $5.00, suggesting a potential upside of 13.12%. Enliven Therapeutics has a consensus target price of $70.50, suggesting a potential upside of 15.37%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Enliven Therapeutics had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Enliven Therapeutics and 3 mentions for Arbutus Biopharma. Enliven Therapeutics' average media sentiment score of 1.19 beat Arbutus Biopharma's score of 1.19 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Enliven Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Summary

Arbutus Biopharma beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Arbutus Biopharma has a net margin of 83.95% compared to Gemini Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Arbutus Biopharma	83.95%	129.32%	112.24%

Arbutus Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Arbutus Biopharma	$14.08M	62.01	-$33.50M	$0.83	5.33

Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 13.12%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Arbutus Biopharma had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Arbutus Biopharma and 0 mentions for Gemini Therapeutics. Arbutus Biopharma's average media sentiment score of 1.19 beat Gemini Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Arbutus Biopharma	Positive

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Summary

Arbutus Biopharma beats Gemini Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to IDEAYA Biosciences?

Arbutus Biopharma (NASDAQ:ABUS) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

In the previous week, IDEAYA Biosciences had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for IDEAYA Biosciences and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat IDEAYA Biosciences' score of 0.75 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to IDEAYA Biosciences' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Arbutus Biopharma currently has a consensus price target of $5.00, suggesting a potential upside of 13.12%. IDEAYA Biosciences has a consensus price target of $50.25, suggesting a potential upside of 39.16%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe IDEAYA Biosciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arbutus Biopharma has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.01	-$33.50M	$0.83	5.33
IDEAYA Biosciences	$218.71M	14.51	-$113.70M	-$1.60	N/A

Summary

Arbutus Biopharma beats IDEAYA Biosciences on 10 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

43.8% of Arbutus Biopharma shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arbutus Biopharma has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Arbutus Biopharma	$14.08M	62.01	-$33.50M	$0.83	5.33

In the previous week, MBX Biosciences had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for MBX Biosciences and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat MBX Biosciences' score of 0.85 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

MBX Biosciences presently has a consensus price target of $71.13, indicating a potential upside of 0.60%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 13.12%. Given Arbutus Biopharma's higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Arbutus Biopharma has a net margin of 83.95% compared to MBX Biosciences' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Arbutus Biopharma	83.95%	129.32%	112.24%

Summary

Arbutus Biopharma beats MBX Biosciences on 11 of the 16 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$873.13M	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	5.33	7.36	279.72	25.54
Price / Sales	62.01	1,274.64	648.71	115.96
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	11.05	17.08	11.12	6.36
Net Income	-$33.50M	-$12.52M	$3.48B	$347.58M
7 Day Performance	0.23%	2.52%	2.59%	3.17%
1 Month Performance	-9.24%	-5.36%	-2.79%	-2.06%
1 Year Performance	32.34%	51.37%	64.29%	21.19%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	2.0056 of 5 stars	$4.42 +1.4%	$5.00 +13.1%	+33.3%	$873.13M	$14.08M	5.33	90	Positive News Upcoming Earnings Gap Up
ARQT Arcutis Biotherapeutics	3.7198 of 5 stars	$27.84 +1.8%	$34.00 +22.1%	+81.5%	$3.42B	$376.07M	N/A	150	Positive News Upcoming Earnings
ELVN Enliven Therapeutics	2.5874 of 5 stars	$52.74 -0.4%	$70.50 +33.7%	+209.9%	$3.22B	N/A	N/A	50	Positive News
GMTX Gemini Therapeutics	N/A	$74.12 -2.3%	N/A	+30.6%	$3.21B	N/A	N/A	30	High Trading Volume
IDYA IDEAYA Biosciences	3.8159 of 5 stars	$36.77 +3.9%	$50.25 +36.7%	+45.9%	$3.11B	$225.27M	N/A	80	News Coverage Earnings Report Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. ARQT, ELVN, GMTX, IDYA, and MBX

How does Arbutus Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Arbutus Biopharma compare to Enliven Therapeutics?

Summary

How does Arbutus Biopharma compare to Gemini Therapeutics?

Summary

How does Arbutus Biopharma compare to IDEAYA Biosciences?

Summary

How does Arbutus Biopharma compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. ARQT, ELVN, GMTX, IDYA, and MBX

How does Arbutus Biopharma compare to Arcutis Biotherapeutics?

Does the media prefer ABUS or ARQT?

Do analysts recommend ABUS or ARQT?

Which has more volatility and risk, ABUS or ARQT?

Is ABUS or ARQT more profitable?

Do insiders & institutionals believe in ABUS or ARQT?

Which has better earnings & valuation, ABUS or ARQT?

Summary

How does Arbutus Biopharma compare to Enliven Therapeutics?

Do insiders and institutionals hold more shares of ABUS or ELVN?

Which has stronger earnings and valuation, ABUS or ELVN?

Do analysts rate ABUS or ELVN?

Does the media favor ABUS or ELVN?

Which has more volatility and risk, ABUS or ELVN?

Is ABUS or ELVN more profitable?

Summary

How does Arbutus Biopharma compare to Gemini Therapeutics?

Is GMTX or ABUS more profitable?

Which has better valuation and earnings, GMTX or ABUS?

Do analysts rate GMTX or ABUS?

Do institutionals & insiders hold more shares of GMTX or ABUS?

Does the media favor GMTX or ABUS?

Which has more risk & volatility, GMTX or ABUS?

Summary

How does Arbutus Biopharma compare to IDEAYA Biosciences?

Does the media prefer ABUS or IDYA?

Which has more volatility and risk, ABUS or IDYA?

Is ABUS or IDYA more profitable?

Do analysts prefer ABUS or IDYA?

Do institutionals and insiders hold more shares of ABUS or IDYA?

Which has better earnings and valuation, ABUS or IDYA?

Summary

How does Arbutus Biopharma compare to MBX Biosciences?

Do insiders & institutionals hold more shares of MBX or ABUS?

Which has better valuation and earnings, MBX or ABUS?

Does the media favor MBX or ABUS?

Which has more risk & volatility, MBX or ABUS?

Do analysts recommend MBX or ABUS?

Is MBX or ABUS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools